ZY Jan 2023 20.000 call
| Previous close | 0.2000 |
| Open | 0.2000 |
| Bid | 0.0000 |
| Ask | 4.8000 |
| Strike | 20.00 |
| Expiry date | 2023-01-20 |
| Day's range | 0.2000 - 0.2000 |
| Contract range | N/A |
| Volume | |
| Open interest | 2.96k |
- Motley Fool
Why Biotech Disruptor Ginkgo Bioworks Is Well-Positioned for the Future
Beaten down from its highs late last year, cell engineering company Ginkgo Bioworks now looks primed to divide and conquer.
- PR Newswire
Ginkgo to Acquire Zymergen
Today, Ginkgo Bioworks (NYSE: DNA) — the leading horizontal platform for cell programming — and the biotechnology company Zymergen (Nasdaq: ZY) announced they have entered into a definitive agreement under which Ginkgo will acquire Zymergen in an all-stock transaction that values Zymergen at an approximately $300 million market capitalization. Under the terms of the agreement, which have been unanimously approved by the boards of directors of both companies, Zymergen stockholders will receive a
- GlobeNewswire
Zymergen Expands Agreement with Octant to Scale Next-Generation Drug Discovery Platform
Octant doubles its initial investment in Zymergen’s Automation Technology to significantly increase the scale and throughput of its drug discovery platformEMERYVILLE, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”) today announced it has expanded its agreement with Octant to further scale their next-generation platform to develop breakthrough medicines. In May, Octant purchased five Reconfigurable Automation Carts, or RACs, to improve the throughput, efficie
